Back to Search

BMS-986528 for Difficult-to-Treat Rheumatoid Arthritis

A Study of BMS-986528 in Participants With Refractory Rheumatoid Arthritis

Recruiting Phase 1 Phase 2 Interventional Study
Arthritis, Rheumatoid
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 65
Sex
Any
Trial phase
Phase 1/2
Study type
Interventional
Purpose
Treatment
Participants needed
84 (estimated)
Sponsor
Bristol-Myers Squibb · Industry
Who this trial is looking for

This trial is looking for adults with rheumatoid arthritis that is hard to treat. Participants will take a medication called BMS-986528 and help researchers understand its effects.

Are You a Good Fit for This Trial?

You may be able to join if

  • I am an adult with rheumatoid arthritis.

You may not be able to join if

  • I was diagnosed with juvenile arthritis or had inflammatory arthritis before age 18.
  • I have seronegative rheumatoid arthritis and have not ruled out polymyalgia rheumatica.
  • I have active fibromyalgia that interferes with joint assessment.

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and the preliminary evidence of disease-modifying effect of BMS-986528 in participants with refractory, difficult-to-treat rheumatoid arthritis (RA).

Trial Locations

Loading trial locations…

Eligibility Criteria
Inclusion Criteria \- Adult participants with rheumatoid arthritis (RA) who meet definition of difficult-to-treat. Exclusion Criteria * Juvenile arthritis or onset of inflammatory arthritis before age 18. * Seronegative RA participants in whom polymyalgia rheumatica has not been ruled out. * Acti…
Contacts

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com

855-907-3286

Clinical.Trials@bms.com

CONTACT

First line of the email MUST contain NCT # and Site #.

CONTACT

NCT ID: NCT07412704 Source: ClinicalTrials.gov